In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ventana rejects Roche takeover bid

This article was originally published in The Gray Sheet

Executive Summary

Tissue-based diagnostics firm Ventana rejects Roche's $3 billion hostile takeover bid as "inadequate" July 11. Roche, which hopes to pair the technology with its targeted cancer drugs for advanced personalized medicine, had announced the offer June 25. The diversified drug and diagnostics giant responded to Ventana's dismissal of the offer in a same-day letter, stating that if there is "additional information that would support a valuation in excess of our offer, we would be willing to consider it in a negotiation." Roche adds that if a negotiated transaction is not possible, it will continue with its $75-per-share cash tender offer, launched June 27, and consider taking the issue directly to Ventana's shareholders at the firm's 2008 annual meeting. "Such action may include the nomination of new directors to Ventana's board and/or proposals to amend Ventana's bylaws," Roche says (1"The Gray Sheet" July 2, 2007, p. 10)...

You may also be interested in...

Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid

Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says

India Lifts Export Restrictions

India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.

Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC

EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts